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VDACon channel (VDAC), located in the mitochondrial outer membrane, functions as
gatekeeper for the entry and exit of mitochondrial metabolites, and thus controls cross-talk between
mitochondria and the cytosol. VDAC also serves as a site for the docking of cytosolic proteins, such as
hexokinase, and is recognized as a key protein in mitochondria-mediated apoptosis. The role of VDAC in
apoptosis has emerged from various studies showing its involvement in cytochrome c release and apoptotic
cell death as well as its interaction with proteins regulating apoptosis, including the mitochondria-bound
isoforms of hexokinase (HK-I, HK-II). Recently, the functional HK–VDAC association has shifted from being
considered in a predominantly metabolic light to the recognition of its major impact on the regulation of
apoptotic responsiveness of the cell. Here, we demonstrate that the HK–VDAC1 interaction can be disrupted
by mutating VDAC1 and by VDAC1-based peptides, consequently leading to diminished HK anti-apoptotic
activity, suggesting that disruption of HK binding to VDAC1 can decrease tumor cell survival. Indeed,
understanding structure–function relationships of VDAC is critical for deciphering how this channel can
perform such a variety of differing functions, all important for cell life and death. By expressing VDAC1
mutants and VDAC1-based peptides, we have identiﬁed VDAC1 amino acid residues and domains important
for interaction with HK and protection against apoptosis. These include negatively- and positively-charged
residues, some of which are located within β-strands of the protein. The N-terminal region of VDAC1 binds
HK-I and prevents HK-mediated protection against apoptosis induced by STS, while expression of a VDAC N-
terminal peptide detaches HK-I-GFP from mitochondria. These ﬁndings indicate that the interaction of HK
with VDAC1 involves charged residues in several β-strands and in the N-terminal domain. Displacing HK,
serving as the ‘guardian of the mitochondrion’, from its binding site on VDAC1 may thus be exploited as an
approach to cancer therapy.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionIt is now well established that mitochondria play a critical role in
the regulation of apoptosis in mammalian cells by acting as reservoirs
for apoptotic proteins. In response to various apoptotic stimuli, several
apoptogenic factors, such as cytochrome c and Smac/DIABLO, are
released from the intermembrane space of mitochondria into the
cytoplasm, where they initiate the activation of downstream destruc-
tive programs, including the caspase cascade (reviewed in [1,2]). It
remains unclear, however, how these apoptotic initiators cross the
outer mitochondrial membrane (OMM) and are released into theC; mVDAC, murine VDAC; RuR,
ndent anion channel
, Ben-Gurion University of the
atz).
ll rights reserved.cytosol. While somemodels predict that such release is facilitated by a
swelling of the mitochondrial matrix and subsequent rupture of the
OMM, other models suggest the formation of protein-conducting
channels that are large enough to allow the passage of cytochrome c
and other proteins into the cytosol, without compromising the
integrity of the OMM [3]. The ﬁnding that cytochrome c can leak
from intact mitochondria [4] supports these latter models. Accord-
ingly, accumulating evidence indicates that the voltage-dependent
anion channel (VDAC) is involved in the release of apoptogenic
proteins via the OMM [5–12]. It should be noted, however, that
multiple routes to apoptosis, including VDAC-independent pathways,
exist [13].
VDAC lies at a crucial position in the cell, forming the main
interface between themitochondrial and cellular metabolisms. VDAC
constitutes a major pathway by which metabolites, such as NAD+/
NADH, ADP/ATP, succinate, citrate, and ions, such as Ca2+, are ex-
changed between the cytosol and mitochondria [9,14,15]. Although
VDAC plays a major role in the physiological processes of solute
and metabolite transport, it is also recognized as a key protein in
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have focused on VDAC as an essential player in apoptosis as well as on
the contribution of VDAC to the function of mitochondria in cell life
and death [5–12]. VDAC, believed to participate in the release of
cytochrome c and to interact with anti- and pro-apoptotic proteins, is
considered a likely candidate for the OMM pore-forming protein
[7,10,11,16,17]. In fact, various stimuli were shown to trigger apoptosis
by modulation of VDAC, implicating VDAC1 as a component of the
apoptosis machinery [10,12,16,18–20].
The role of VDAC in apoptosis also emerged from demonstrations
of interactions between VDAC and proteins regulating apoptosis. In
fact, the ﬁrst such demonstration was documented 21 years ago in a
study by Nakashima et al. [21] in which a form of hexokinase (HK),
now known to be HK-II was shown to bind to VDAC in the OMM of a
rapidly growing cancer cell line. Later many other studies demon-
strated interactions of VDAC with the mitochondrial-bound isoforms
of hexokinase, HK-I and HK-II and with proteins from the Bcl2 family
[22–34]. In particular, mammalian HK-I and HK-II were shown to bind
to the OMM via interacting with VDAC [10,11,22,23,26–28,34,35]. By
binding to VDAC, HK gains direct access to the mitochondrial ATP pool
for phosphorylation of glucose [36]. Indeed, one of the signature
phenotypes of highly malignant, poorly differentiated tumors is their
remarkable propensity to utilize glucose at a much higher rate than
normal cells, a property frequently dependent on the marked over-
expression of HK [37–39]. HK thus lies at the apex of the glycolytic
pathway that provides those metabolic intermediates required by the
biosynthetic pathways on which a transformed cell places such heavy
demand [40].
Recently, however, the functional HK–VDAC association has shifted
from being considered in a predominantly metabolic light to
recognition of its major impact on the regulation of apoptotic
responsiveness of the cell. Recent studies from our own and other
groups have demonstrated that HK can inhibit apoptosis by binding to
VDAC and preventing release of cytochrome c [11,22,23,26,28,34].
Hence, controlling both bioenergetics and cell death, the HK-
mitochondria interaction has been considered as a target for anti-
cancer drugs in recent years [11,40–43]. Two main classes of agents
affect the HK-mitochondria association. The ﬁrst class includes
competitive and/or allosteric compounds, i.e. inhibitors of HK activity
[11,43–46]. The second class includes compounds that compete with
VDAC for HK binding, such as VDAC1-based peptides [41], or with HK
for VDAC binding sites, such as the peptide representing the N-
terminal hydrophobic domain of HK, shown to effectively displace HK
from VDAC [24,28].
In this study, we provide insight into the function of VDAC1 in
apoptosis and into the regulation of mitochondria-mediated apopto-
sis, while characterizing the interaction of HK with VDAC and
characterizing the protection against apoptosis HK affords.
2. Materials and methods
2.1. Materials
Poly-D-lysine (PDL), propidium iodide and staurosporine (STS)
came from Sigma (St. Louis, MO). Mito-Tracker red dye CMXPos
was from Molecular Probes, Invitrogen (Eugene, OR). Monoclonal
anti-VDAC antibodies raised to the N-terminal region of VDAC1
came from Calbiochem-Novobiochem (Nottingham, UK), while
rabbit polyclonal anti-VDAC antibodies, prepared against amino
acids 150–250 of hVDAC1, were from Abcam. Monoclonal anti-
cytochrome c antibodies were obtained from BD Biosciences
Pharmingen (San Jose, CA). Monoclonal anti-GFP antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Horse-
radish peroxidase-conjugated anti-mouse antibodies were obtained
from Promega (Madison, WI). Metafectene was purchased from
Biotex (Munich, Germany). RPMI 1640 and DMEM growthmedia andthe supplements, fetal calf serum (FCS), L-glutamine and penicillin-
streptomycin, were purchased from Biological Industries (Beit
Haemek, Israel). Blasticidin and Zeocin were purchased from In-
vivoGen (San Diego, CA). Puromycin was purchased from ICN Bio-
medicals (Eschwege, Germany).
2.2. Plasmids and site-directed mutagenesis
DNA encoding mVDAC1, the LP1, LP2, LP3 and LP4 peptides was
generated and cloned into the tetracycline-inducible pcDNA4/TO
vector (Invitrogen), as described previously [41]. The four VDAC1
loop-based peptides, LP1 to LP4, were ﬂanked by a tryptophan zipper
motif, i.e. the SWTWE amino acid sequence, at the N-terminus of the
peptide and the KWTWK sequence at the C-terminus. The pcDNA3-
HK-II and pcDNA3.1-HK-I plasmids were kindly provided by J.E.
Wilson (Michigan State University). pEGFP-HK-I and pEGFP-HK-II,
encoding GFP connected to the HK-I C-terminal, were generated as
described [23].
2.3. Cell culture
MCF7 represents a human breast carcinoma cell line, HEK-293
cells correspond to a transformed primary human embryonal kidney
cell line, T-REx-293 cells are tetracycline repressor-expressing HEK-
293 cells and HeLa cells are derived from cervix cancer. hVDAC1-
shRNA T-REx-293 were grown in Dulbecco's modiﬁed Eagle's medium
(Biological Industries), supplemented with 10% fetal calf serum, 2 mM
L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, (all from
Biological Industries) and maintained in a humidiﬁed atmosphere, at
37 °C with 5% CO2. hVDAC1-shRNA T-REx-293 cells stably ex-
pressing the pSUPERretro vector encoding shRNA-targeting
hVDAC1 were transfected with plasmids pcDNA4/TO-mVDAC1,
grown as described [18] for 76 to 96 h prior to a 5 h exposure to
STS (1.25 μM). Over-expression of mVDAC1- or Δ(26)mVDAC1-
pcDNA4/TO was induced by tetracycline (2.5 μg/ml) for 96–112 h
and cell viability was analyzed by acridine orange (AcOr) and
ethidium bromide (EtBr) staining, as described previously [34].
HEK-T cells were transiently co-transfected with plasmids pEGFP-
HK-I and pcDNA/4TO-mVDAC1, or plasmids encoding LP1, LP3 or
LP4 peptides, grown for 48 h with tetracycline (1 μg/ml) and then
visualized by confocal microscopy.
2.4. Confocal microscopy
HEK-T cells (3×105) were grown on PDL-coated coverslips in a
60 mm dish and transfected with pEGFP-HK-I or other plasmids, as
indicated in ﬁgure or table legends. After 48 h, cells were stained with
MitoTracker red dye (15 nM), washed with PBS, ﬁxed for 20 min with
4% paraformaldehyde and rinsed with PBS prior to imaging by
confocal microscopy (Olympus 1X81).
2.5. Apoptosis analysis
Apoptosis was analyzed by acridine orange/ethidium bromide
staining [34] or by propidium iodide PI uptake and FACS analysis.
2.6. Protein puriﬁcation and single-channel recording and analysis
mVDAC1 and E72Q-mVDAC1 were expressed in the Saccharomyces
cerevisiae por1-mutant strain M22-2 [34] or puriﬁed from mitochon-
dria [9]. HK-I was puriﬁed from rat brain mitochondria [22].
Reconstitution of puriﬁed native and E72Q-mVDAC1 into a planar
lipid bilayer (PLB), channel recording, and analysis were carried out as
described [47].
3. Results
It has been shown that over-expression of human, murine, yeast
or rice VDAC1 induces apoptotic cell death, regardless of cell
type [18,23,34,48]. On the other hand, the interaction of HK-I with
VDAC and protection against cell death as induced by VDAC1 over-
Table 1
Over-expression of recombinant HK-I protects against apoptotic cell death as induced
by over-expression of native but not of certain VDAC1 mutants
Experiment Cells transfected to express: Apoptotic cells (%) Protection (%)
−HK-I +HK-I
I U-937 cells
Control 2.9±0.7 3.1±0.4
mVDAC1-GFP 73.1±3.0 9.3±3.1 91
E65Q-mVDAC1-GFP 65.3±4.2 71.1±3.6 0
E72Q-mVDAC1-GFP 80.0±3.9 78.9±6.3 0
K73L-mVDAC1-GFP 69.4±2.3 73.6±1.3 0
D77N-mVDAC1-GFP 72.5±2.1 68.7±2.4 0
II T-REx-293 cells
Control 3.4±0.6 4.1±0.3
mVDAC1 74.5±2.8 8.2±2.6 93.4
G67A-mVDAC1 71.8±10.8 9.0±1.2 91.9
N75A-mVDAC1 74.6±2.6 8.7±2.9 92.7
E202Q-mVDAC1 79.2±1.6 66.0±3.7 17.4
III T-REx-293 cells
Control 9.8±0.8 13.0±0
mVDAC1 44.7±1.7 10.5±2.2 97
K20S-mVDAC1 41.9±2.2 37.0±6.7 15.5
G21A-mVDAC1 44.9±0.9 45.6±1.3 0
In experiment (I), U-937 cells were transfectedwith plasmid pcDNA3.1-HK-I and grown
in the presence of 400 μg/ml neomycin, as described previously [23,34]. The cells were
then transfected with pEGFP-N1, encoding native or the indicated mutated VDAC1 and
grown in the presence of neomycin (400 μg/ml) for 76 h before analysis of apoptotic
cells. In experiment (II), four samples of TREx-293 cell were transfectedwith pcDNA3.1-
HK-I. 48 h later, the expression level of HK-I was analyzed by Western blot. The cell
sample with the highest HK-I expression level was selected for a second transfection
with pcDNA4/TO encoding native or the indicated mutated VDAC1. Transfected cells
were grown for 96 h in the presence of tetracycline (2.5 μg/ml) to induce VDAC1 over-
expression. Apoptotic cells were then analyzed. In experiment (III), T-REx-293 cells
were co-transfected with pcDNA3.1-HK-I and pcDNA4/TO, encoding mVDAC1, K20S-
mVDAC1, G21A-mVDAC1 or E72Q-mVDAC1. Co-transfected cells were grown for 112 h
with tetracycline (2.5 μg/ml) and apoptotic cells were then analyzed. Apoptotic cell
death was visualized by acridine orange/ethidium bromide staining. Quantitative
analysis of apoptosis in the different cells was performed by ANOVA and t tests versus
control cells. Data shown are the mean±S.E.M (n= 3).
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34,41].
Table 1 summarizes the effects of HK-I over-expression on
apoptotic cell death induced by native and various mVDAC1 mutants.
HK-I-mediated protection against apoptosis was analyzed by expres-
sion of native or mutated mVDAC1 in U-937 cell, T-REx-293 or
hVDAC1-shRNA T-REx-293 cells, the latter resenting cells suppressed
for endogenous VDAC1 expression [18], as well as in the same cell
lines over-expressing HK-I. HK-I elicited protection against apoptosis
induced by over-expression of native and some, but not other VDAC1
mutants. The latter group includes VDAC1 containing mutations at
glutamates 65 and 72, aspartate 77, lysine 73, as well as glutamates
188 and 202. The locations of the various mutations in the VDAC1
sequences proposed to be involved in HK interaction are depicted in
the previously proposed [15,49] and recently presented [50–52]
VDAC1 structural models shown in Fig. 1.
The inability of HK-I to interact with E72Q-VDAC1 was also
demonstrated by analyzing the effects of HK-I on the conductance of
E72Q-mVDAC1 reconstituted into a planar lipid bilayer (PLB) (Fig. 2).
Puriﬁed recombinant native and E72Q-mVDAC1 were PLB-reconsti-
tuted and channel conductance, before and after addition of puriﬁed
HK-I were recorded, as a function of the voltage applied (Fig. 2). Upon
addition of HK-I to native mVDAC1, channel conductance was
reduced at all voltages tested. On the other hand, HK-I had no effect
on the conductance of E72Q-mVDAC1. These results suggest that E72
is essential for HK-I interaction with VDAC1 and/or modifying its
conductance.
To demonstrate that HK-I does not interact with other VDAC1
mutants, we co-expressed E72Q- or E188Q-mVDAC1 and a HK-I-GFP
fusion protein in HEK-T cells. Confocal ﬂuorescence microscopyshowed that HK-I-GFP ﬂuorescence is punctuated in cells transiently
expressingmVDAC1(Fig. 3). On the other hand, HK-I-GFP ﬂuorescence
in cells expressing either E72Q- or E188Q-mVDAC1 was diffused
throughout the cytosol. These results indicate that HK-I does not bind
to the mutated VDAC1, in agreement with HK inability to confer
protection against cell death (Table 1).
Based on these and previously published results [23,34,41], we
deﬁned the domains and amino acid residues involved in stabilizing
VDAC1 conformation interacting with HK-I (Fig. 1). These VDAC1
regions were expressed in HEK-T cells in the form of the loop-shaped
peptides, LP1W, LP2Wand LP4W (Fig. 4A), and their effects on the HK-
I-GFP interaction with mitochondria were analyzed (Fig. 4B). Peptide
LP3W served as a control peptide since it did not interact with HK-I
and had no effect on HK-I-mediated protection against apoptosis [41].
Fig. 4B demonstrates that the peptides can modify HK-I-GFP cellular
distribution by detaching mitochondria-bound HK-I. Confocal ﬂuor-
escence microscopy showed that in control cells expressing HK-I-GFP,
the ﬂuorescence is punctuated, as expected for a mitochondrial
distribution. On the other hand, HK-I-GFP ﬂuorescence in cells
expressing the LP1, to lesser extent the LP2 or LP4 peptides (but not
peptide LP3) was diffused throughout the cytosol (Fig. 4B). These
results indicate that the expressed VDAC1-based peptide detach or
prevent HK-I binding to the mitochondria.
The function of the N-terminal region of VDAC1 in the interaction
with HK-I and cell death was demonstrated using an N-terminal
truncated version of VDAC1 [Δ(26)VDAC1]. As shown in Fig. 5, upon
transfection of HEK-293, MCF7 or HeLa cells with mVDAC1, about
10–15% of the cells underwent apoptosis by the third day. This
level was increased to 50% by day ﬁve (Fig. 5A), due to VDAC1
overexpression (Fig. 5C) [8,10,18,23,34]. Apoptotic cell death was
reﬂected as enhanced nuclear fragmentation, visualized by acridine
orange/ethidium bromide staining (Fig. 5B). By contrast, cells
expressing Δ(26)mVDAC1 showed 8–15% apoptosis by day 3, a
level that did not change by the ﬁfth day of expression. It should be
mentioned that these cells express endogenous hVDAC1, and al-
though this VDAC represents about 40% and the N-terminal-trun-
cated mVDAC1 60% of the VDAC pool (Fig. 5C), the effect of the
latter is dominant, suggesting that the mutant displays a dominant
negative effect (see also [53]).
Finally, not only VDAC1-based peptides can detach HK-I-GFP from
its binding site in VDAC, but also chemicals such as clotrimazole
(CTM), an anti-fungal azole derivative that, at high concentrations
(e.g. 20 μM) has been shown to dissociate HK-II from mitochondria in
several cell types [24,28]. Here, we demonstrate the ability of CTM to
detach mitochondria-bound HK-I-GFP. The punctuated HK-I-GFP
ﬂuorescence, co-localized with MitoTracker, a dye that speciﬁcally
labels mitochondria in living cells, was converted to diffuse labeling of
the cytosol and did not co-localize withMitoTracker in the presence of
CTM (Fig. 6A). CTM also induced cell death (Fig. 6B).
4. Discussion
In this study, we addressed the function of VDAC1 in apoptotic
cell death and in the regulation of apoptosis via interaction with
anti-apoptotic proteins, in particular HK. We and others have
explored the N-terminal of VDAC1 as a key element in apoptosis
induction and addressed its involvement in apoptosis regulation by
HK and Bcl2 [30,53,54] (and Fig. 6). This discussion will thus focus
on the HK–VDAC interaction, an interaction sufﬁcient to allow cells
to evade apoptosis. Indeed, the notion that the abundant expres-
sion of HK-I and HK-II in most cancer cells occurs only to ensure
energy supplies has changed, with HK having been deﬁned as an
important regulator of mitochondrial function in both normal and
cancer cells [40,43]. Hence, HK has become known as the ‘guardian
of mitochondria’ and as such, displacing HK from its binding site in
VDAC1 may be exploited as a cancer therapy approach.
Fig. 1. VDAC1 transmembrane topology models, previously proposed (A) and recently demonstrated (B), highlighting the amino acids mutated and the sequences used for peptides expression. The amino acids mutated in the N-terminus and
other domains of VDAC1 are labeled in the previously proposed transmembrane topology (A) [15] and in the newly established structure (B) [50–52]. Green circled amino acids indicate that mutation of these amino acids eliminates HK-I-
mediated protection against cell death. Amino acids indicated in red squares, when mutated, had no effect on HK-I-mediated protection against apoptosis. The positions of the sequences of the ﬁve peptides (yellow-labeled), expressed as
peptides and tested in this work, are illustrated.
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Fig. 2. Hexokinase-based modiﬁcation of channel conductance of planar lipid bilayer-
reconstituted native and mutated VDAC. Multi-channel recordings of the average
steady-state conductance of native mVDAC1 or E72Q-mVDAC1 before (closed circles)
and 10 min after the addition of HK-I (28.6 mU/ml) (open circles) are shown as a
function of voltage. Relative conductance was determined as the ratio of conductance at
a given voltage (G) to the maximal conductance (Go). The experiments shown are
representative of 4–5 similar experiments.
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The VDAC1 amino acid residues and domains involved in the
interaction with HK-I or HK-II have recently been identiﬁed
[23,34,41,53]. Certain point mutations in VDAC1 prevented HK-I
binding, resulting in HK-I being no longer able to prevent cytochrome
c release and subsequent apoptosis in cells over-expressing such
VDAC1 mutants ([23,34] and Table 1). These mutations include the
charged glutamate residues 65 and 72, aspartate 77 and lysine 73,
located in the same sequence region, and glutamate 188 and 202
found in another VDAC1 region. According to previously proposed
VDAC1 membrane topology models [15,49,55], most of the mutated
amino acids listed above were predicated to be exposed to the cytosol.
However, according to recently described NMR-based [50,52] and X-
ray crystallography-based [51] VDAC1 structure, some but not all of
these mutations are located in cytosolic-facing sequences (Fig. 1). The
E72Qmutation that interrupts the interaction between VDAC1 and HK
was also found to induce increases in mitochondrial swelling and
OXPHOS activity, as well as to reduce in mitochondrial membrane
cholesterol levels [56].
The N-terminal portion of VDAC1 has been shown to interact with
HK-I, as channel conductance of N-terminal truncated VDAC1 was not
modiﬁed by HK-I [53]. Accordingly, a synthetic peptide corresponding
to the N-terminal region of VDAC1 both binds HK-I and prevents HK-I-
and HK-II-mediated protection against apoptosis induced by STS
[41,53]. Expression of the N-terminal peptide was found to detach HK-
I-GFP from mitochondria, supporting the interaction of HK-I with the
N-terminal region of VDAC1 [41]. These ﬁndings indicate that the
interaction of HK with VDAC1 involves charged residues in several β-
strands and the N-terminal domain. Recent VDAC1 structural analysis
suggests a conformational cross-talk between Glut 72 (Glu-73 whenFig. 3. HK-I-GFP imaging of cells expressing native or mutated VDAC1. HEK-T cells were transi
encoding E188Q-VDAC1, E72Q-VDAC1 or mVDAC1 and visualized after 30 h using a confocal
three similar experiments.counting the ﬁrst Met) and the N-terminal part of the VDAC1 [50]. By
hydrogen/deuterium exchange coupled to NMR spectroscopy, it has
been shown that the N-terminal portion of hVDAC1 (residues in
β1–β4) possesses conformational instability and switches between
different VDAC1 conformations [50]. Interestingly, the structural
instability of the N-terminal part was found to be particularly
inﬂuenced by Glu-73 [50], which is required for HK-I- and HK-II-
mediated modiﬁcation of channel conductance (Fig. 2 and [23,34]).
According to the recently established hVDAC1 3D-structure, Glu-73
points to the membrane to interrupt the amphipathic pattern in
strand β4. Mutations that replace the charged Glu-73 with glutamine
[23,34] or valine [50] resulted in stabilization of the β1–β4 strands
[50]. Such mutations abolished both ruthenium red (RuR)- and HK-I-
mediated inhibition of VDAC channel activity and RuR- and HK-I-
mediated protection against apoptosis [23,34,57]. Thus, in accord with
a recent suggestion [50], the conformational ﬂexibility of the β-
strands (β1–β4) is, in addition to the N-terminal region, important for
voltage gating and for the interaction of VDAC1with HK and RuR, both
in vitro and in vivo.
It has been shown that HK interacts with themitochondria through
its N-terminal 12 amino acid hydrophobic sequence (MIAAQLLAYYFT)
[28,58,59]. HK might interact thorough its N-terminal region with the
amphipatic α-helix N-terminal portion of VDAC1.
On the other hand, the ﬁndings presented here indicate that the
interaction of HK with VDAC1 involves charged residues. As a highly
hydrophobic sequence, the N-terminal of HK cannot directly engage
essential charged VDAC1 residues. VDAC1 charged residues may thus
be involved in stabilizing the HK-binding VDAC1 conformation.
However, the interaction of synthetic VDAC1-based peptides with
HK ([41] and Fig. 4), suggests that sequences within these domains are
involved in the interaction of VDAC1 with HK. This suggests that HK
interacts with several domains of VDAC1, which may explain the
detachment of HK by various compounds (see below).
The VDAC1–HK interaction can also apparently be regulated by
Glu-6-P and multiple protein kinases (e.g. glycogen synthase kinase
(GSK)-3beta [27] and protein kinase C (PKC)), resulting in phosphor-
ylation of VDAC itself or of HK [60]. It was also recently shown that
over-expression of HK stimulated VDAC phosphorylation through a
PKCɛ-dependent pathway [61]. It should be noted, however, that
VDAC phosphorylation has not been detected by others [62].
4.2. Possible mechanisms by which the detachment of mitochondria-
bound HK could lead to cell death
The balance between cytosolic HK-I and mitochondria-bound HK
is important in the regulation of glycolysis, depending on physio-
logical conditions and variations in intracellular distribution that
could serve as a regulatory mechanism [63,64]. The association
between increased HK expression and cell survival is well demon-
strated [22,23,28,34,41,64,65]. Several mechanisms have beenently transfected to express HK-I-GFP alone or co-transfected with plasmid pcDNA/4To,
microscope (scale bar=5 μm). Images are representative microscopic ﬁelds from one of
Fig. 4. Detachment of mitochondria-bound HK-I-GFP by VDAC1-based peptides. (A) Schematic presentation of a representative VDAC1-derived peptide (LP1) ﬂanked with a
tryptophan zipper, as formed by introducing the tryptophan zipper motif, i.e. the SWTWE amino acid sequence at the N-terminal of the peptide and KWTWK at the C-terminal [41].
These sequences induce the formation of a stable β-hairpin and thus, mimic a VDAC1 loop found in the native protein. (B) HEK-T cells (3×105) were transfected using CaPi to express
HK-I-GFP alone or with plasmid pcDNA/4To encoding peptide LP1, LP2, LP3 or LP4. After 48 h, cells were visualized using a confocal microscope. Images are representative
microscopic ﬁelds from one of three similar experiments (scale bar=5 μm).
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anti-apoptotic defense, all involving interaction with VDAC1. HK
bound to VDAC on the mitochondrial surface provides both a
metabolic beneﬁt and apoptosis-suppressive capacity that gives the
cell a growth advantage and increases its resistance to chemother-
apy [40]. Mitochondria-bound HK-I and HK-II have direct access to
mitochondrial sources of ATP and greater afﬁnity for MgATP
supplied by mitochondria [66,67]. In addition, HK bound to the
cytosolic face of VDAC acts as a gate, regulating channel ion
conductivity (Fig. 2 and [22]). Moreover, mitochondria-bound HK-I
is also less sensitive to inhibition by Glu-6-P (CI50 of 5 mM,
compared with 0.1 mM for the soluble form of the enzyme) [22].
Thus, disruption of the HK–VDAC interaction should interfere with
the energy balance of highly demanding cancer cells.
HK-I and HK-II over-expression in cells growing in tissue culture
protects against cell death [22,23,27,34,41,68]. The anti-apoptoticFig. 5. The N-terminal region of VDAC1 is required for apoptotic cell death and HK-I anti-ap
(black columns) or Δ(26)mVDAC1 (grey columns), with their over-expression being induce
day, as visualized by acridine orange/ethidium bromide staining. Quantitative analysis of apo
means±S.E.M. (n= 4). (B) Apoptotic cell death visualized by acridine orange/ethidium br
nuclei (stained with acridine orange). Arrow head indicates the late apoptotic state (staine
analysis of VDAC levels in control cells and cells transfected to express mVDAC1 or Δ(26)
controls, actin levels in the samples (15 μg) were compared, using anti-actin antibodies.effect of HK is mediated through its binding to VDAC, preventing
cytochrome c release by closing the mitochondrial release pore [22]
or/and by preventing Bax translocation to the mitochondria and
subsequent apoptosis [28]. Moreover, it has been shown that
dissociation of HK from mitochondria induces cytochrome c release
and apoptosis, even in cells deﬁcient for both Bak and Bax [24]. Thus,
if, as suggested, HK–VDAC interaction lies at the heart of apoptosis
regulation by HK, interfering with HK binding to VDAC could form the
basis for novel cancer treatment.
The mechanism(s) by which HK dissociation from mitochondria
leads to apoptosis is not clear. Several possible mechanisms may be
considered. As presented above, detachment of mitochondria-bound
HK affects mitochondrial and overall cellular bioenergetics. Indeed,
agents known to detach mitochondrial HK also induce ATP
depletion preceding the decrease in cell viability [69,70]. Another
possible mechanism involves the high sensitivity of cytosolic HK tooptotic effect. (A) HEK-293, HeLa and MCF-7 cells were transfected to express mVDAC1
d by 2.5 μg/ml tetracycline. Cell viability was determined on day three and on the ﬁfth
ptosis in the different treatments was performed by ANOVA and t test; pb0.01. Data are
omide staining. Arrow indicates cells in an early apoptotic state, reﬂected by degraded
d with acridine orange and ethidium bromide) (scale bar=15 μm). (C) Western blot
mVDAC1 (30 μg) using polyclonal and monoclonal anti-VDAC antibodies. For loading
Fig. 6. Clotrimazole (CTM) detachesmitochondria-boundHK-I-GFP. (A) HEK-Tcells (3×105)were transfected to express HK-I-GFP and after 48 h, were exposed for 2 h to the indicated
concentrations of CTM, treatedwithMitoTracker, as described inMaterials andmethods, and visualized using a confocal microscope (scale bars=12.5 μm for the left column and 5 μm
for the other columns). The right panel shows themerged images ofMitoTracker andHK-I-GFP. Images are representativemicroscopic ﬁelds fromone of three similar experiments. (B)
HEK-T cells were treated with 20 μM CTM for 11 h or with 0.1% DMSO for control cells in a medium containing 1% FCS. Cell viability was detected by PI uptake and analyzed by FACS.
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reduce energy production for high energy-demanding cancer cells.
In addition, HK-I was shown to inhibit PTP opening [22,71], while
Glu-6-P favored PTP opening [22,68], presumably by detaching HK
from its binding site [22,46]. Thus, high levels of Glu-6-P not only
inhibit HK catalytic activity but also promote PTP opening, and
thereby, induction of apoptosis. In addition, as pointed out above,
HK-I and HK-II binding to VDAC is decreased by high concentrations
of Glu-6-phosphate, leading to their release, thereby allowing for
activation of apoptosis [22,72,73].
Another possible mechanism involves the regulation of ROS
production by HK. It had been shown that mitochondrial HK activity
fulﬁlled a key role as a preventive anti-oxidant against oxidative stress,
reducing mitochondrial ROS generation through an ADP-recycling
mechanism [74]. Expression of HK-II was found to protect against
oxidant-induced cell death [75], while HK-I over-expression in an
established epithelial cell line leads to protection against oxidation-
induced cell death [76]. It was also demonstrated that HK-I and HK-II
reduce intracellular levels of ROS [61]. In addition, while glucose
increased the rate of oxygen consumption and reduced the rate of H2O2
generation, Glu-6-P increased H2O2 generation [74]. Thus, over-
expression of mitochondria-bound HKI and HKII protects cells against
damage from oxidative stress. Accordingly, detachment of HK from its
binding site in the mitochondria could lead to increased H2O2
generation, thereby activating cell death. These ﬁndings suggest that
mitochondrial HK activity is pivotal for the physiological functions of
mitochondria.
Another possible mechanism for cell death induced by disruption
of HK–VDAC complex may involve an interaction of Bax with the
mitochondria. The HK–VDAC interaction changes the susceptibility of
mitochondria to pro-apoptotic signals mediated through Bcl2-family
proteins, such as Bax [28]. One of the proposed models by which Bax
would mediate cytochrome c release from mitochondria involves the
formation of a Bax/VDAC complex [77,78]. It has been shown that
VDAC-bound HK renders cells much more resistant to activation of
apoptosis by Bax or Bak [28,79]. It has also suggested that Bax and Bid
may promote apoptosis by displacing HK from VDAC [28,79]. For this
activity, the C-terminal of Bax is required since Bax-ΔC was unable to
displace HK or liberate cytochrome c from the reconstituted HK–
VDAC–ANT (adenine nucleotide translocase) complex [80]. Accord-
ingly, displacement of HK from its binding site in VDAC, by either
means, would permit the actions of Bax/Bak in mediating apoptosis.
Regardless of the exact mechanism by which dissociation of HK
from mitochondria promotes apoptosis, the results presented here
strongly suggest that mitochondria-bound HK plays a critical role in
mammalian mitochondrial-dependent apoptosis.
4.3. Disruption of the HK–VDAC interaction as an approach to cancer
therapy
One of the major hallmarks of tumor cells is their relative
resistance against cell death, owing to over-expression of anti-
apoptotic proteins of the Bcl2 family and HK [38,39,81–83]. As
discussed above, it has been shown that a HK–VDAC1 interaction
prevents induction of apoptosis in tumor-derived cells
[22,23,26,28,34,41,58]. Thus, promoting detachment of HK from
VDACmay be a promising cancer therapy strategy. Several compounds
have been shown to induce dissociation of HK from the mitochondria
and apoptosis. These include peptides corresponding to the amino
terminus of both HK-I [58] and HK-II [28], clotrimazole ([28,84] and
Fig. 6), a cell permeable peptide corresponding to the amino-terminal
23 residues of HK-II fused to six arginines at the carboxyl-terminus
(N-HK-II) [79], methyl jesmonate [85] and VDAC1-based peptides
([41] and Fig. 4). The VDAC1-based peptides interacted with puriﬁed
HK-I, detached HK bound to mitochondria isolated from tumor cells
and in cells displaced mitochondria-bound HK-I-GFP ([41] and Fig. 4).These ﬁndings suggest that interfering with the binding of HK to
mitochondria by VDAC1-based peptides may offer a novel strategy by
which to augment apoptosis and enhance the synergistic therapeutic
efﬁcacy of conventional chemotherapeutic agents and reducing dose-
limiting toxicity.
HK-inhibiting compounds, including glucose metabolites, 2-deox-
yglucose, oxamate and 3-bromopyruvate, selectively induce apoptosis
in cancer cells and in pre-clinical models of cancer showed selective
toxicity against tumor cells metabolizing anaerobically [43,86–88].
These agents act to kill cancer cells by interacting with HK, however,
whether these compounds detach HK from its binding sites in the
mitochondria is still not clear. It is, nonetheless, proposed that these
drugs are likely to enhance the efﬁcacy of the current standard cancer
chemotherapeutics and radiation regimens.
Recently [85], we have shown that a plant stress hormone of
the jasmonate family, methyl jasmonate (MJ), binds to HK in a
speciﬁc manner, leading to its detachment from mitochondria
isolated from several cancer cell types. The susceptibility of cancer
cells to jasmonates is dependent on the expression of HK. This
ﬁnding, thus, provides an explanation for the selective effects of
jasmonates on cancer cells. It should be noted that intra-arterial
injection of 3-bromopyruvate, an inhibitor of mitochondria-bound
HK, into tumors implanted in rabbit liver killed up to 90% of the
tumor cells without signiﬁcant damage to the surrounding healthy
tissue [86].
To conclude, this and other studies discussed here strongly indicate
that HK and VDAC are key components in the regulation of apoptosis
and that the protective effects of HK against cell death are mediated
via its direct interaction with VDAC. Furthermore, these results
suggest that HK over-expression in cancer cells not only assures an
adequate supply of energy, but also corresponds to an anti-apoptotic
defensemechanism. Accordingly, interferingwith HK binding to VDAC
can serve to guide development of a new selective approach for cancer
therapy.
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